GC Genome announced on January 19 that it achieved a turnaround to profitability, reporting provisional results for the previous year with annual revenue of 31.5 billion won and operating profit of 1.2 billion won. Revenue increased by 5.6 billion won (22%) compared to the previous year's 25.9 billion won, and operating profit improved by 2.5 billion won from -1.2 billion won in the previous year, returning to the black.
This improvement in performance is attributed to a balanced increase in sales across all testing areas-including obstetrics, oncology, rare genetic diseases, and health checkups-with high growth in the obstetrics and checkup divisions, which include key new businesses, driving overall revenue expansion. According to the company, the number of 'iCanSearch' health checkup tests rose from 900 in 2024 to 5,100 in 2025, while the core obstetric test, the non-invasive prenatal test (G-NIPT), increased from 18,000 to 25,200 cases during the same period.
In terms of profitability, economies of scale were realized as the number of test requests increased. The rise in testing volume eased the burden of fixed costs such as personnel and equipment, and the cost-to-sales ratio fell by 1 percentage point year-on-year, leading to the turnaround to profitability.
The non-operating segment also contributed to the results. The company secured about 43 billion won in public offering funds through its initial public offering (IPO) in June of last year, which led to increased interest income and expanded net financial income. Its cash holdings also grew from 6.5 billion won in the previous year to 40.1 billion won. In addition, the increased value of its equity holdings due to the merger of its affiliates, Zenith Health and GC Labtech, was reflected as an increase in other income.
GC Genome plans to continue its growth in revenue and profitability by expanding the domestic and international reach of its major testing products.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
